ADAP - Adaptimmune says mid-stage trial for afami-cel in soft tissue cancer will meet main goal

Adaptimmune Therapeutics (ADAP -0.5%) announced that its ongoing SPEARHEAD-1 trial for afami-cel in advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) would meet the primary endpoint based on the overall response rate (ORR). The company is on track to report updated data from the pivotal Phase 2 trial on Friday at the Connective Tissue Oncology Society (CTOS) annual meeting. “We are confident that these data will support our BLA filing for afami-cel next year,” Adaptimmune (NASDAQ:ADAP) Chief Medical Officer, Elliot Norry, remarked. As of data cut-off on Sep. 01, 50 patients (42 with synovial sarcoma and 8 with MRCLS) had received afami-cel (also known as afamitresgene autoleucel and formerly called ADP-A2M4). Based on 47 evaluable patients, ORR stood at 34% (16/47 patients with partial responses [PRs]). ORR for patients with synovial sarcoma and MRCLS stood at 36% and 25%, respectively. Based on the independent review, the disease control rate had reached

For further details see:

Adaptimmune says mid-stage trial for afami-cel in soft tissue cancer will meet main goal